Telo Genomics Corp (TSE:TELO) has released an update.
Telo Genomics Corp has announced the inclusion of its TeloViewSMM test for detecting high-risk smoldering multiple myeloma (SMM) patients in the CAP’s approved list of laboratory tests. This approval allows the test, which has demonstrated high sensitivity and specificity, to be used in U.S. hospitals and clinics. The TeloViewSMM test aids in the timely treatment of high-risk patients and monitoring of low-risk patients, potentially improving myeloma disease management.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
